New antibiotic GSK3882347 tested for UTIs in early trial

NCT ID NCT05138822

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental antibiotic called GSK3882347 in 140 women with uncomplicated urinary tract infections (UTIs). Participants received either the new drug, a standard antibiotic (nitrofurantoin), or a placebo for 5 days. The study measured how well the drug cleared bacteria from urine and monitored for side effects. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK3882347 (an experimental antibiotic)
What this could lead to: If successful, this could lead to a new antibiotic option for uncomplicated urinary tract infections in women.
What could go wrong: This is an early phase 1b trial with only 140 participants, so safety and effectiveness are not yet proven. The drug may not work better than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCOMPLICATED URINARY TRACT INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial urinary tract infection escherichia coli infection urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNCOMPLICATED URINARY TRACT INFECTIONS URINARY TRACT INFECTIONS

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Anniston, Alabama, 36207, United States
GSK Investigational Site

Lomita, California, 90717, United States
GSK Investigational Site

Modesto, California, 95350-5365, United States
GSK Investigational Site

Doral, Florida, 33166, United States
GSK Investigational Site

Miami, Florida, 33186, United States
GSK Investigational Site

Miami Lakes, Florida, 33016-1507, United States
GSK Investigational Site

Palmetto Bay, Florida, 33157, United States
GSK Investigational Site

Sweetwater, Florida, 33172, United States
GSK Investigational Site

Chicago, Illinois, 60643, United States
GSK Investigational Site

The Bronx, New York, 10456, United States
GSK Investigational Site

Smithfield, Pennsylvania, 15478, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Dallas, Texas, 75230, United States
GSK Investigational Site

Houston, Texas, 77061, United States
GSK Investigational Site

Missouri City, Texas, 77459, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.